At the upcoming congress of the European Society for Medical Oncology (ESMO), Eli Lilly (NYSE: LLY) will present a range of new data, including on the investigational compound pegilodecakin.
Lilly picked up pegilodecakin through its $1.6 billion all-cash acquisition of California’s ARMO BioSciences earlier this year, part of a strategic move to make waves in the immuno-oncology space.
Pegilodecakin is a PEGylated interleukin (IL)-10 which has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze